Streetbeat News

Earnings

PRM

Perimeter Solutions reported a slight decrease in Q3 EPS from $0.99 to $0.98 year-over-year, while sales increased from $174.26 million to $195.41 million.

Portfolio Pulse from Bill Haddad

December 14, 2021 | 11:11 am

OXM

Oxford Industries has raised its FY21 adjusted EPS guidance to $7.52-$7.67, surpassing the previous estimate of $6.71. The company also expects sales to be between $1.127 billion and $1.137 billion, exceeding the earlier estimate of $1.11 billion.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2021 | 9:09 pm

OXM

Oxford Industries has provided guidance for Q4, expecting EPS between $1.20 and $1.35, compared to the $1.30 estimate. Sales are projected to be between $285M and $295M, surpassing the $281.4M estimate.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2021 | 9:08 pm

UDMY

Udemy reported its Q3 earnings with an EPS of $(0.04), which was in line with expectations. The company achieved sales of $129.60 million, surpassing the estimated $125.89 million.

Portfolio Pulse from Bill Haddad

December 08, 2021 | 9:07 pm

ULTA

Analysts have raised their price targets for Ulta Beauty Inc (NASDAQ:ULTA) following its Q3 results that exceeded expectations and an increased FY21 outlook. Despite the positive outlook, the stock is trading lower by 1.25% at $378.83.

Portfolio Pulse from Shivani Kumaresan

December 03, 2021 | 5:56 pm

OOMA

Ooma projects its Q4 2022 revenue to be between $49.7 million and $50.2 million, surpassing the estimated $48.77 million.

Portfolio Pulse from Benzinga Newsdesk

December 02, 2021 | 9:23 pm

DKS

Dick's Sporting Goods has raised its full-year 2022 adjusted EPS guidance to $14.60-$14.80, surpassing the previous estimate of $13.13.

Portfolio Pulse from Bill Haddad

November 23, 2021 | 12:34 pm

MRMD

MariMed, Inc. (OTCQX:MRMD) reported significant growth in its Q3 financial results, with a 213% YoY increase in adjusted EBITDA and a 147% increase in revenue. The company reaffirmed its full-year revenue guidance of $118M and adjusted EBITDA of $42M. Operational highlights include substantial growth in revenue from retail dispensary operations and wholesale sales of cannabis products. Despite a 7.45% decrease in share price to $0.87, the company remains optimistic about meeting its full-year financial targets.

Portfolio Pulse from Jelena Martinovic

November 16, 2021 | 7:33 pm

BHVN

Biohaven Pharmaceutical reported a Q3 EPS of $(1.91), beating the estimate of $(2.40). The company's sales reached $135.74 million, surpassing the expected $128.40 million.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2021 | 12:47 pm